Preeti Trisal

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Clinical Cancer Research · 2011 · 285 citations · Full text

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2015 · 280 citations

Anti-trop-2/sn-38 Antibody–drug Conjugate, Immunology, Immunoediting +20

Improving the Therapeutic Index in Cancer Therapy by Using Antibody–Drug Conjugates Designed with a Moderately Cytotoxic Drug

Serengulam V. Govindan, Thomas M. Cardillo, Edmund A. Rossi et al. · Molecular Pharmaceutics · 2014 · 60 citations

Immunology, Immunotherapeutics, Moderately Cytotoxic Drug +21

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

Hsiling Chiu, Preeti Trisal, Chad C. Bjorklund et al. · British Journal of Haematology · 2019 · 47 citations · Full text

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro

Thomas M. Cardillo, Preeti Trisal, Roberto Arrojo et al. · BMC Cancer · 2013 · 33 citations · Full text